GenMont Biotech Incorporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 87.93 million compared to TWD 95.49 million a year ago. Net income was TWD 2.89 million compared to TWD 11.72 million a year ago. Basic earnings per share from continuing operations was TWD 0.03 compared to TWD 0.14 a year ago. Diluted earnings per share from continuing operations was TWD 0.03 compared to TWD 0.14 a year ago.
For the six months, sales was TWD 167.55 million compared to TWD 186.45 million a year ago. Net income was TWD 11.13 million compared to TWD 35.02 million a year ago. Basic earnings per share from continuing operations was TWD 0.13 compared to TWD 0.41 a year ago. Diluted earnings per share from continuing operations was TWD 0.13 compared to TWD 0.4 a year ago.